Literature DB >> 6784569

Gentamicin, tobramycin, and sisomicin disc susceptibility tests. Revised zone standards for interpretation.

A L Barry, C Thornsberry, R N Jones, E H Gerlach.   

Abstract

Studies were undertaken to reevaluate interpretive zone standards for gentamicin and tobramycin disc tests. Disc tests with an investigational aminoglycoside, sisomicin, were also evaluated. The data suggest modification of zone standards for gentamicin disc tests to R (resistant) less than or equal to 12 mm and S (susceptible) greater than or equal to 16 mm. Currently recommended standards for tobramycin disc tests (R less than or equal to 12 mm and S greater than or equal to 15 mm) were found to be satisfactory. For 10-microgram sisomicin discs, zone standards of R less than or equal to 12 mm and S greater than or equal to 15 mm were also appropriate. Although gentamicin is structurally similar to sisomicin, it was less active against Pseudomonas aeruginosa. The activity spectrum of sisomicin against the collection of 470 bacterial isolates studied more nearly resembled that of tobramycin. Data analysis suggested that tobramycin disc tests might be used to predict susceptibility to sisomicin. However, these two drugs differ in their susceptibilities to aminoglycoside-inactivating enzymes produced by some resistant strains. In those institutions where such strains are endemic, the class concept of disc testing may not be applicable.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6784569     DOI: 10.1093/ajcp/75.4.524

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Comparative evaluation of the micro-media system, sceptor, and MIC-2000 microdilution methods for testing Pseudomonas aeruginosa against gentamicin, tobramycin, and amikacin.

Authors:  B F Woolfrey; R T Lally; C O Quall
Journal:  J Clin Microbiol       Date:  1983-02       Impact factor: 5.948

2.  Pseudomonas aeruginosa ATCC 49189, a new quality control strain for testing P. aeruginosa susceptibility to the aminoglycosides.

Authors:  R T Lally; B F Woolfrey; M A Enright
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

3.  Evaluation of Aminoglycoside and Carbapenem Resistance in a Collection of Drug-Resistant Pseudomonas aeruginosa Clinical Isolates.

Authors:  Selina Y L Holbrook; Sylvie Garneau-Tsodikova
Journal:  Microb Drug Resist       Date:  2017-12-20       Impact factor: 3.431

4.  Modification of interpretive breakpoints for netilmicin disk susceptibility tests with Pseudomonas aeruginosa.

Authors:  A L Barry; G H Miller; R S Hare; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-03       Impact factor: 5.948

5.  Error rates associated with the use of recently proposed breakpoints for testing Pseudomonas aeruginosa versus gentamicin, tobramycin, and amikacin by the standardized disk agar diffusion test.

Authors:  B F Woolfrey; J M Fox; C O Quall; R T Lally
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

6.  Broth microdilution testing of Pseudomonas aeruginosa and aminoglycosides: need for employing dilutions differing by small arithmetic increments.

Authors:  B F Woolfrey; J M Fox; R T Lally; C O Quall
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.